Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive rhIL-2 Therapy in MDR-TB
NCT03069534Phase 3Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2009
- Primary completion
- Jun 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aldesleukin in multidrug-resistant tuberculosis (MDR-TB) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Cure rate at 130 months. Status: unknown.
02
Drugs
aldesleukin
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on NCT03069534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03069534.